CTIS.eu › Cities › France › Nantes Cedex 1
Nantes Cedex 1
France
92 total trials
45 recruiting
2024-516549-37-00
4
2021-04-12
Treatment of Parkinson’s disease (PD)
2023-509171-16-00
5
2020-11-23
Classic Congenital Adrenal Hyperplasia (CAH)
2024-515331-30-00
7
2020-10-30
Primary Central Nervous System Lymphoma (PCNSL)
2023-505219-19-00
9
2019-09-03
Relapsed or refractory multiple myeloma (RRMM) and newly diagnosed MM
2024-512470-10-00
11
2018-02-02
End-stage Renal disease
2024-512212-21-00
5
2017-11-28
Advanced hepatocellular carcinoma (HCC)
2023-508567-75-00
9
2025-01-29
Gastro-Entero-Pancreatic Neuroendocrine Neoplasms
2022-500642-25-00
4
2024-11-21
MRSA patients
2023-504809-37-00
5
2024-02-07
Symptomatic Obstructive Hypertrophic Cardiomyopathy
2022-501476-25-00
5
2023-09-12
Atopic Dermatitis
Eczema
2022-501783-18-00
4
2023-07-21
Parkinson’s Disease
2022-500121-33-01
5
2023-05-08
Anti-GBM antibody disease (Goodpasture disease)
2022-500079-30-00
5
2022-11-03
IgA Nephropathy
2024-511066-36-00
5
2021-10-13
Light Chain (AL) Amyloidosis
2024-511381-36-00
5
2021-10-13
Chronic Myelogenous Leukemia in chronic phase (CML-CP)
2024-516670-29-00
4
2020-09-15
Multiple Myeloma
2024-515985-16-00
5
2019-04-25
Herpes Simplex Virus Encephalitis
2024-516416-22-00
10
2019-01-17
malignancy of thyroid nodules
2024-516750-21-00
9
2015-10-14
Patients with relapsed / refractory Mantle Cell Lymphoma
2024-518931-12-00
4
2014-05-15
Neuroblastoma
Showing 73–92 of 92 trials